RIANA team had an incredible time running! The energy, teamwork, and camaraderie made it unforgettable. We were proud to send two teams of three this year, and the best part? We improved our results from 2023!
It was a perfect day to step away from the lab, have fun, and strengthen our bond as a team. We’re already planning our next sporty challenges, and I couldn’t be more excited. Huge thanks to everyone at RIANA for creating such a fantastic atmosphere – here’s to more shared adventures!
From left to right: Anna, Dominika, Anna, Tobias, Angela and Christine
We are delighted to announce that RIANAtx will be attending the BIO-EUROPE partnering conference, from November 4th to November 11th in the beauftiful city of Stockholm.
We look forward to presenting our recent data and connecting with leading business executives and early-stage investors in the life sciences and biotech community to foster new and exciting business opportunities!
Vienna, June 2024. We are pleased to announce the formation of our Scientific Advisory Board (SAB), which includes leading experts in the field of cancer research and small molecule development. This milestone marks a significant step forward in our mission to demonstrate how our platform screening approach for protein-protein interaction inhibitors and our pipeline molecules can improve the lives of cancer patients.
Anna Quattropani, PhD VP Chemisty Anavo Tx, Expert in medicinal chemistry
Anna brings over 20 years of experience in medicinal chemistry and drug discovery, with a strong track record of advancing clinical candidates through to Phase 2/3. She has invented small molecules for neurodegenerative diseases and reproductive health. Her expertise spans targeted protein degradation, enzyme inhibition, GPCR modulation, and protein-protein interactions across various therapeutic areas. Currently SVP of Chemistry and Non-Clinical Development at Anavo Therapeutics, Anna holds 48 patents in oral and CNS small molecule drug discovery, medicinal chemistry, and synthetic organic chemistry.
Jürgen Moll, PhD Ex-Boehringer Ingelheim, Expert in cancer drug development
Jürgen is a distinguished expert in cancer research and preclinical drug development, focusing on cancer cell targeting and immuno-oncology with small molecules, antibodies, and nanobodies. He has advanced oncology drugs at big pharma companies like Novartis, Pfizer, and Sanofi, as well as biotech spin-offs. Jürgen has held leadership roles at Sanofi, Boehringer-Ingelheim, and Nerviano Medical Sciences. An international consultant, SAB member, and lecturer, he holds a PhD in Biochemistry from the University of Basel and a degree in Microbiology from the University of Bayreuth.
Peter Nussbaumer, PhD KHAN/LDC, Expert in medicinal chemistry
Peter has over 30 years of industry experience in drug discovery. Before joining the LDC, he held key roles in medicinal chemistry at Sandoz and Novartis, most recently as Executive Director and Senior Unit Head of Chemistry at Novartis Institutes for Biomedical Research. He has managed numerous drug discovery projects and coordinated interdisciplinary and international teams. Peter has published extensively in peer-reviewed journals, is a co-inventor on several patents, and holds a PhD in organic chemistry from the University of Technology, Vienna.
Prof. Richard Moriggl, PhD Co-founder, Expert in STAT/JAK Biology
Prof. Moriggl is a leading expert in STAT biology, with significant contributions to understanding STAT3/5 signaling in normal and cancer cells. He was a Professor for Functional Cancer Genomics at Vetmeduni Vienna from 2014 to 2022 and has been a successful PI for 17 years, overseeing personnel, funding, and scientific management. As director of the Ludwig Boltzmann Institute for Cancer Research for 14 years, he shaped a successful research program and managed an annual budget of up to €2.5 million.
Congratulations to our brilliant scientist, Tobias Suske, on publishing his PhD study in the high-impact Journal of Clinical Investigation (JCI)!
In this paper, Tobias explored molecular mechanisms of how mutated hyperactive STAT5 causes T cell acute lymphoblastic leukemia (T-ALL). His work sheds light on the mechanisms underlying this disease and validates STAT5 as a key target in T-ALL and cancer.
We couldn’t be prouder to have him as part of our team, driving innovation and pushing scientific discovery’s boundaries.
We are delighted to announce that RIANAtx will be attending the LSX World Congress, from April 29th to April 30th in the vibrant city of London.
We look forward to presenting our recent data and connecting with early-stage investors in the life sciences and biotech community to foster new and exciting business opportunities!
We are delighted to announce that RIANAtx will be attending the BIO-EUROPE SPRING partnering conference, from March 18th to March 20th in the beauftiful city of Barcelona.
We look forward to presenting our recent data and connecting with leading business executives and early-stage investors in the life sciences and biotech community to foster new and exciting business opportunities!
In our endeavor to connect with leading business executives and early-stage investors in the life science and biotech community, it was a great pleasure to participate in the Inv€$tival Showcase and present our company in the “Startup Biotech” category.
We are delighted to announce that RIANAtx will be attending the BIO-EUROPE partnering conference, from November 6th to 8th in Munich, Germany.
We look forward to connecting with leading business executives and early-stage investors in the life sciences and biotech community to foster new and exciting business opportunities!
Vienna, Austria, and Dortmund, Germany, September 12 2023
RIANA Therapeutics, a spin-off from Vetmeduni Vienna founded in February 2023, announces that is has entered into a collaborative agreement with the Lead Discovery Center GmbH (LDC), a renowned organization specialized in translational drug discovery. This partnership marks the first important milestone on RIANA Therapeutics´ mission to discover and develop novel cancer therapeutics that disrupt oncogenic protein-protein interactions (PPIs).
Inhibition of PPIs is an emerging drug modality and a highly promising therapeutic approach for numerous diseases, including cancer, to overcome widespread resistance to drugs already in use and to improve treatment efficacy. Under the now-signed collaboration agreement, LDC will conduct a high-throughput screening (HTS) using a diverse compound library of more than 200,000 chemical substances to identify novel PPI inhibitors targeting STAT5, a critical mediator driving the development of Acute Myeloid Leukemia (AML).
Through the strategic partnership with LDC, RIANA Therapeutics secures invaluable access to LDC’s profound expertise in the field of early drug discovery. By combining their respective strengths, RIANA Therapeutics and LDC aim to accelerate the translation of innovative discoveries into potential therapeutics, with the declared long-term goal of improving the well-being of patients on a global scale.
Anna Orlova, co-founder and CEO of RIANA Therapeutics, expressed her excitement about the collaboration: “We are thrilled to partner with LDC, a highly experienced player in drug discovery. Their expertise and capabilities will be instrumental in our efforts to develop breakthrough therapeutics for hematopoietic and other cancer types. This collaboration marks a significant milestone for RIANA Therapeutics, and we look forward to working together to advance our shared mission of improving human health.”
Peter Nussbaumer, Managing Director at LDC, added: “We are highly motivated to start the challenging discovery of inhibitors targeting oncogenic PPI interactions within this new partnership with RIANA. This cooperation has the great potential to lay the groundwork for new, urgently needed therapeutic approaches for AML patients.”
From left to right: Oliver Szolar, Peter Nussbaumer, Anna Orlova, Christine Ruckenbauer, Richard Moriggl
About RIANA
RIANA Therapeutics was founded in February 2023 as a spin-off of Vetmeduni in Vienna founded by Anna Orlova, Richard Moriggl, and Oliver Szolar. The technological foundation is based on a proprietary platform technology for the discovery of compounds that target cancer-promoting protein-protein interactions (PPI), enabling a reliable search for inhibitors that block the formation of specific oncogenic PPIs. Building upon this novel proprietary technology, the team led by Orlova is working on developing new compounds specifically targeting AML, as well as other blood cancers and certain types of solid tumors.
Lead Discovery Center GmbH (LDC) was established in 2008 by the technology transfer organization Max Planck Innovation, as a novel approach to capitalize on the potential of excellent basic research for the discovery of new therapies for diseases with high medical need. The LDC takes on promising early-stage projects from academia and transforms them into innovative pharmaceutical leads and antibodies that reach initial proof-of-concept in animals as well as candidate nomination. In close collaboration with high-profile partners from research and industry, the LDC is building a strong and growing portfolio of small molecule and antibody leads with exceptional medical and commercial potential.
LDC sustains a long-term partnership with the Max Planck Society and its institutes as well as with KHAN-I, and has formed alliances with AstraZeneca, Bayer, Boehringer Ingelheim, Merck KGaA, Daiichi Sankyo, Qurient, InvIOS, Novo Nordisk, Cumulus Oncology, Nodus Oncology, JT Pharmaceuticals, KinSea AS, HLB Pharma, the Helmholtz Center for Infection Research, e.g. In addition, LDC also works with leading translational drug discovery centers and with various investors to provide its assets for company creation.
RIANA Therapeutics, ein Spin-off der Veterinärmedizinischen Universität Wien (Vetmeduni) entwickelt innovative Krebsmedikamente. Diese richten sich gezielt gegen krebsfördernde Protein-Protein-Wechselwirkungen.
RIANA Therapeutics 